Jump to:

ValiRx Fundamentals

Company Name ValiRx Last Updated 18 Mar 2019
Industry Health Care Sector Pharmaceuticals & Biotechnology
Shares in Issue (m) 681.63 Market Cap (£m) 3.61
PE Ratio -0.28 Div per Share (p) 0.00
Div Yield 0.00 Div Cover 0.00
EPS -1.90 EPS Growth (%) 77.75
PEG -0.00 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing 21.94 Gross Gearing 36.14
Asset Equity Ratio 1.57 Cash Equity Ratio 22.23
Quick Ratio 1.13 Current Ratio 1.13
Price To Book Value 1.15 ROCE -112.34

ValiRx Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

ValiRx Company Financials

Assets (£m) 2017 2016 2015
Tangible Assets 0 0 0
Intangible Assets 3 3 3
Investments 0 0 0
Total Fixed Assets 3 3 3
Stocks 0 0 0
Debtors 1 1 1
Cash & Equivalents 1 1 0
Other Assets 1 0 1
Total Assets 5 5 5
Liabilities (£m) 2017 2016 2015
Creditors within 1 year 2 3 1
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 2 3 1
Net assets 3 2 5
Equity (£m) 2017 2016 2015
Called up share capital 8 8 8
Share Premium 16 13 11
Profit / Loss -4 -6 -3
Other Equity 2 2 1
Preference & Minorities -0 0 0
Total Capital Employed 3 2 5
Ratios 2017 2016 2015
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing 21.94 40.95 6.95
Gross Gearing 36.14 52.26 11.48
Assets / Equity 1.57 2.10 1.13
Cash / Equity 22.23 23.68 5.12
EPS -1.90 -8.54 -6.66
Cash Flow (£m) 2017 2016 2015
Cash from operating activities -2 -5 0
Cashflow before financing -3 -3 0
Increase in Cash 0 0 0
Income (£m) 2017 2016 2015
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -3 -4 -3
Pre-Tax profit -4 -6 -3
Profit / Loss for the year 8 8 8

ValiRx Company Background

Sector Pharmaceuticals & Biotechnology
Activities ValiRx Plc is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in precision medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention. The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Latest Interim Date 25 Sep 2018
Latest Fiscal Year End Date 10 Apr 2018

ValiRx Directors

Appointed Director Position
03 Oct 2006 Dr Satu Vainikka Chief Executive Officer
12 May 2006 Gerald Desler Finance Director
02 Jun 2011 Oliver de Giorgio-Miller Non-Executive Chairman
06 Mar 2007 Kevin John Alexander Non-Executive Director
04 Oct 2013 Seppo Olavi Makinen Non-Executive Director
03 Oct 2006 Dr George Stephen Morris Non-Executive Director

ValiRx Contact Details

Company Name ValiRx
Company Address 24 Greville Steet, London EC1N 8SS.
Company Telephone +44 (0)203 008 4416
Company Website http://www.valirx.com/

ValiRx Advisors

Auditor Name Adler Shine LLP
Auditor Address Aston House, Cornwall Avenue, London N3 1LF.
Auditor Website http://www.adlershine.com/
Auditor Telephone +44 (0)20 8371 3000
Registrar Name Capita Registrars
Registrar Address The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
Registrar Website http://www.capitaregistrars.com/
Registrar Telephone 0870 162 3100
Broker Name Daniel Stewart & Company
Broker Address Becket House, 36 Old Jewry, London EC2R 8DD.
Broker Website http://www.danielstewart.co.uk/
Broker Telephone +44 (0) 207 776 6550
Adviser Name Cairn Financial Advisers
Adviser Address 38 Bow Lane, London EC4M 9AY.
Adviser Website http://www.cairnfin.com/
Adviser Telephone +44 (0)20 7148 7901
Solicitor Name Bircham Dyson Bell
Solicitor Address 50 Broadway, London SW1H 0BL.
Solicitor Website http://www.bdb-law.co.uk/
Solicitor Telephone +44 (0)20 7227 7000
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a